drugset / Trial / NCT02320045

Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

NCT02320045

Phase 1 Completed 38 enrolled Intarcia Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Phase 1 study to evaluate the pharmacokinetics of ITCA 650 in subjects with mild and moderate renal impairment compared to the pharmacokinetics of subjects with normal renal function

Timeline

Start
2014-11
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide